Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo

Christian B.M. Poulie, Emanuel Sporer, Lars Hvass, Jesper T. Jørgensen, Paul J. Kempen, Sara I. Lopes van den Broek, Vladimir Shalgunov, Andreas Kjaer*, Andreas I. Jensen*, Matthias M. Herth*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

86 Downloads (Pure)


Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively. Thus, they can be used for drug delivery purposes. Bioorthogonal chemistry allows for a pretargeting approach. Higher target-to-background drug accumulation ratios can be achieved. Pretargeting can also be used to induce internalization processes or trigger controlled drug release. Colloidal gold nanoparticles (AuNPs) have attracted widespread interest as drug delivery vectors within the last decades. Here, we demonstrate for the first time the possibility to successfully ligate AuNPs in vivo to pretargeted monoclonal antibodies. We believe that this possibility will facilitate the development of AuNPs for clinical use and ultimately, improve state-of-the-art patient care.

Original languageEnglish
Article numbere2022018
JournalChemistry - A European Journal
Issue number61
Publication statusPublished - 2022


Dive into the research topics of 'Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo'. Together they form a unique fingerprint.

Cite this